Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial (ZEAL)

De Boer RH, Arrieta O, Yang C-H, Gottfried M, Chan V, Raats J, De Marinis F, Abratt RP, Wolf J, Blackhall FH, Langmuir P, Milenkova T, Read J, Vansteenkiste J

Journal: Journal of Clinical Oncology, Vol 29, No 8, March 2011, doi: 10.1200/JCO.2010.29.5717
Veröffentlichung: März 2011